Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world

被引:47
作者
Million, M. [1 ,2 ]
Gautret, P. [1 ,3 ]
Colson, P. [1 ,2 ]
Roussel, Y. [1 ,2 ]
Dubourg, G. [1 ,2 ]
Chabriere, E. [1 ,2 ]
Honore, S. [4 ,5 ]
Rolain, J. -M [1 ,2 ]
Fenollar, F. [1 ,3 ]
Fournier, P. -E. [1 ,3 ]
Lagier, J. -C. [1 ,2 ]
Parola, P. [1 ,3 ]
Brouqui, P. [1 ,2 ]
Raoult, D. [1 ,2 ]
机构
[1] IHU Mediterranee Infect, 19-21 Blvd Jean Moulin, F-13005 Marseille, France
[2] Aix Marseille Univ, AP HM, IRD, MEPHI, Marseille, France
[3] Aix Marseille Univ, AP HM, IRD, SSA,VITROME, Marseille, France
[4] Hop La Timone, AP HM, Serv Pharm, Marseille, France
[5] Aix Marseille Univ, Lab Pharm Clin, Marseille, France
关键词
Chloroquine; coronavirus; coronavirus disease 2019; hydroxychloroquine; meta-analysis; severe acute respiratory syndrome coronavirus 2;
D O I
10.1016/j.nmni.2020.100709
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
In the context of the current coronavirus disease 2019 (COVID-19) pandemic, we conducted a meta-analysis on the effects of chloroquine derivatives in patients, based on unpublished and published reports available publicly on the internet as of 27 May 2020. The keywords 'hydroxychloroquine', 'chloroquine', 'coronavirus', 'COVID-19' and 'SARS-Cov-2' were used in the PubMed, Google Scholar and Google search engines without any restrictions as to date or language. Twenty studies were identified involving 105 040 patients (19 270 treated patients) from nine countries (Brazil, China, France, Iran, Saudi Arabia, South Korea, Spain and the USA). Big data observational studies were associated with conflict of interest, lack of treatment dosage and duration, and absence of favourable outcome. Clinical studies were associated with favourable outcomes and details on therapy. Among clinical studies, three of four randomized controlled trials reported a significant favourable effect. Among clinical studies, a significant favourable summary effect was observed for duration of cough (OR 0.19, p 0.00003), duration of fever (OR 0.11, p 0.039), clinical cure (OR 0.21, p 0.0495), death (OR 0.32, p 4.1 x 10(-6)) and viral shedding (OR 0.43, p 0.031). A trend for a favourable effect was noted for the outcome 'death and/or intensive care unit transfer' (OR 0.29, p 0.069) with a point estimate remarkably similar to that observed for death (similar to 0.3). In conclusion, a meta-analysis of publicly available clinical reports demonstrates that chloroquine derivatives are effective to improve clinical and virological outcomes, but, more importantly, they reduce mortality by a factor of 3 in patients with COVID-19. Big data are lacking basic treatment definitions and are linked to conflict of interest. The retraction of the only big data study associated with a significantly deleterious effect the day after (June 5, 2020) the acceptance of the present work (June 4, 2020) confirms the relevance of this work. (C) 2020 The Author(s). Published by Elsevier Ltd.
引用
收藏
页数:8
相关论文
共 38 条
  • [1] In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect
    Andreani, Julien
    Le Bideau, Marion
    Duflot, Isabelle
    Jardot, Priscilla
    Rolland, Clara
    Boxberger, Manon
    Wurtz, Nathalie
    Rolain, Jean-Marc
    Colson, Philippe
    La Scola, Bernard
    Raoult, Didier
    [J]. MICROBIAL PATHOGENESIS, 2020, 145
  • [2] [Anonymous], EFFICACY HYDROXYCHLO, DOI 10.1101/2020.03.22.20040758
  • [3] Ashraf MA, 2020, COVID 19 IRAN COMPRE, DOI [10.1101/2020.04.20.20072421, DOI 10.1101/2020.04.20.20072421]
  • [4] Baudrillard Jean., 1981, SIMULACRES SIMULATIO
  • [5] Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection A Randomized Clinical Trial
    Borba, Mayla Gabriela Silva
    Val, Fernando Fonseca Almeida
    Sampaio, Vanderson Souza
    Alexandre, Marcia Almeida Araujo
    Melo, Gisely Cardoso
    Brito, Marcelo
    Mourao, Maria Paula Gomes
    Brito-Sousa, Jose Diego
    Baia-da-Silva, Djane
    Guerra, Marcus Vinitius Farias
    Hajjar, Ludhmila Abrahao
    Pinto, Rosemary Costa
    Balieiro, Antonio Alcirley Silva
    Pacheco, Antonio Guilherme Fonseca
    Santos, James Dean Oliveira, Jr.
    Naveca, Felipe Gomes
    Xavier, Mariana Simao
    Siqueira, Andre Machado
    Schwarzbold, Alexandre
    Croda, Julio
    Nogueira, Mauricio Lacerda
    Romero, Gustavo Adolfo Sierra
    Bassat, Quique
    Fontes, Cor Jesus
    Albuquerque, Bernardino Claudio
    Daniel-Ribeiro, Claudio-Tadeu
    Monteiro, Wuelton Marcelo
    Lacerda, Marcus Vinicius Guimaraes
    [J]. JAMA NETWORK OPEN, 2020, 3 (04) : E208857
  • [6] Borenstein M., 2009, INTRO META ANAL, DOI 10.1002/9780470743386
  • [7] Carlucci P.M., 2020, HYDROXYCHLOROQUINE A, p2020.05.02.20080036, DOI [10.1101/2020.05.02.20080036, DOI 10.1101/2020.05.02.20080036V1, 10.1101/2020.05.02.20080036v1]
  • [8] Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03
  • [9] Chowdhry M, 2020, OUTCOMES HYDROXYCHLO, DOI [10.1101/2020.05.12.20099028, DOI 10.1101/2020.05.12.20099028]
  • [10] Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
    Colson, Philippe
    Rolain, Jean-Marc
    Lagier, Jean-Christophe
    Brouqui, Philippe
    Raoult, Didier
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 55 (04)